Registry-listed formulations

mavorixafor · mesh:C494414

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • X4P-001Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • X4P-001Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • MavorixaforRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • MavorixaforRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • MavorixaforRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
1(11%)
Results Posted
29%(2 trials)

Phase Distribution

Phase 2
2
22%
Phase 3
2
22%
Phase 1
3
33%
Phase 1/2
2
22%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 1/2Combined phases
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(7)

Detailed Status

Completed7
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 1/22 (22.2%)
Phase 22 (22.2%)
Phase 32 (22.2%)

Trials by Status

not_yet_recruiting111%
recruiting111%
completed778%

Recent Activity

1 active trials
Showing 5 of 9
not_yet_recruitingphase_2

A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

NCT07902830
recruitingphase_3

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
completedphase_1

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
completedphase_3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03995108
completedphase_1_2

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

NCT04154488
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07902830Phase 2

A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

Not Yet Recruiting
NCT06056297Phase 3

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Recruiting
NCT06858696Phase 1

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Completed
NCT03995108Phase 3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Completed
NCT04154488Phase 1/2

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
NCT06914869Phase 1

Drug-Drug Interaction Potential of Mavorixafor

Completed
NCT03005327Phase 2

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Completed
NCT02667886Phase 1/2

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Completed
NCT04274738Phase 1

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Completed

All 9 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
9

External References

ChEMBL
CHEMBL518924

Names & Codes

Trade Names

xolremdi

ATC Classification

L03AX24

Research Codes

AMD 070AMD 11070Cxcr4 inhibitor x4p-001X 4P-001